China Health Industries Holding Inc. Debuts on Hong Kong Bourse at HK$81.8, Raises HK$1.019B

According to Zhitong Finance, China Health Industries Holding Inc. (06132) began trading on the Hong Kong Stock Exchange on June 23 at HK$81.8 per share, flat on its IPO price. The company issued 13.6 million shares and raised net proceeds of approximately HK$1.019 billion. Turnover reached HK$389 million in morning session. The biotech firm, founded in 2017, develops therapies for autoimmune, metabolic and oncology diseases. It holds three core product candidates—HJ787, HJ178, and HJ891—all classified as Class 1 novel drugs by China's drug regulator, though none have received commercial approval or generated revenue to date.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments